MWNA
GNMK

Marshall Wace North America’s GenMark Diagnostics, Inc GNMK Stock Holding History

Marshall Wace North America’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-14,544
Closed -$79K – 1845
2018
Q1 		$79K Hold
14,544
– – ﹤0.01% 1375
2017
Q4 		$61K Sell
14,544
-433,110
-97% -$2.61M ﹤0.01% 1325
2017
Q3 		$4.48M Sell
447,654
-96,366
-18% -$1M 0.03% 579
2017
Q2 		$6.53M Buy
544,020
+515,200
+1,788% +$6.59M 0.05% 422
2017
Q1 		$375K Buy
+28,820
New +$347K ﹤0.01% 845
2013
Q4 		$1.12M Buy
84,243
+43,413
+106% +$527K 0.02% 375
2013
Q3 		$496K Buy
+40,830
New +$438K 0.02% 446

Other funds holding GNMK

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Marshall Wace North America's GNMK Position: Q2 2018 in Review

Marshall Wace North America sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2018, closing a stake of 14,544 shares — an estimated $79K sold.

Marshall Wace North America first reported a position in GNMK in Q3 2013 and held it in 7 quarters. The position peaked at $6.53M in Q2 2017. 105 funds tracked by Wall St. Rank hold GNMK as of Q2 2018.

  • Marshall Wace North America reported no remaining GenMark Diagnostics, Inc position as of Q2 2018 after selling out during the quarter.
  • Marshall Wace North America sold 14,544 GenMark Diagnostics, Inc shares in Q2 2018, an estimated $79K.
  • Marshall Wace North America first reported a position in GenMark Diagnostics, Inc in Q3 2013 and held it in 7 quarters.
  • Marshall Wace North America's GenMark Diagnostics, Inc position peaked at $6.53M in Q2 2017.
  • 105 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2018.

Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.